## **CLAIM LISTING**

1. (Previously presented) A compound of the general formula (I):

wherein

R<sup>1</sup> is

C<sub>3-8</sub>-cycloalkyl or C<sub>5-8</sub>-cycloalkenyl,

 wherein the cyclic moieties may optionally be substituted with one or more substituents independently selected from R<sup>12</sup>, wherein R<sup>12</sup> is C<sub>1-6</sub>-alkyl, halogen, trifluoromethyl or 2,2,2-trifluoroethyl.

risl,

s is 0, 1, 2 or 3,

t is 0, 1, 2 or 3,

X is C=0, CHOH or  $CR^2R^3$ ; wherein  $R^2$  and  $R^3$  independently are hydrogen or  $C_{1-6}$ -alkyl, or X is a bond,

Y is is selected from the group consisting of oxadiazolyl, thiadiazolyl, or triazolyl, optionally substituted with one or more substituents independently selected from  $R^{18}$ ,  $R^{18}$  is halogen, nitro, cyano, hydroxy,  $C_{1.6}$ -alkyl,  $C_{1.6}$ -alkylthio or  $C_{1.6}$ -alkoxy;



## R<sup>4</sup> is

(a)  $C_{1-6}$ -alkyl,  $C_{3-8}$ -cycloalkyl or  $C_{3-8}$ -cycloalkenyl, which may optionally be substituted with one or more substituents independently selected from  $R^{13}$ , wherein  $R^{13}$  is  $C_{3-8}$ -cycloalkyl,  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkylthio, cyano, halo- $C_{1-6}$ -alkyl, halo- $C_{1-6}$ -alkoxy, and halogen,

OF

(b) aryl, aryl-C<sub>1-6</sub>-alkyl, aryl-C<sub>2-6</sub>-alkenyl, or heteroaryl

which may optionally be substituted with one or more substituents independently selected from R<sup>14</sup>

R<sup>14</sup> is

- halogen, nitro, cyano, acyl, hydroxy, C<sub>1.6</sub>-alkyl, C<sub>1.6</sub>-alkylthio, C<sub>1.6</sub>-alkylsulfonyl, C<sub>1.6</sub>-alkylsulfonyloxy, C<sub>1.6</sub>-alkoxy, C<sub>3.8</sub>-cycloalkyl, halo-C<sub>1.6</sub>-alkyl, halo-C<sub>1.6</sub>-alkoxy, -NR<sup>5</sup>R<sup>6</sup>, R<sup>5</sup>R<sup>6</sup>N-C<sub>1.6</sub>-alkyl-, R<sup>5</sup>R<sup>6</sup>N-C<sub>1.6</sub>-alkoxy-, or -O(C=O)NR<sup>5</sup>R<sup>6</sup>, or wherein two substituents in adjacent positions together form a radical -O-(CH<sub>2</sub>)<sub>1.3</sub>-O-, wherein R<sup>5</sup> and R<sup>6</sup> independently are hydrogen, C<sub>1.6</sub>-alkyl, C<sub>3.8</sub>-cycloalkyl, C<sub>1.6</sub>-alkanoyl or aryl, or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a 3 to 7 membered, saturated or unsaturated ring, which may be fused to a benzene ring,
- a group of the formula

-(W)<sub>k</sub>-A wherein

W is -C<sub>1-6</sub>-alkyl-, -(O)<sub>1</sub>-C<sub>2-6</sub>-alkenyl-, -(O)<sub>1</sub>-C<sub>1-6</sub>-alkyl-O-, -(CH<sub>2</sub>)<sub>n</sub>-(C=O)-(CH<sub>2</sub>)<sub>m</sub>-, -O-wherein

I is 0 or 1

k is 0 or 1

n and m are independently 0, 1, 2 or 3,

A is

- o aryl, aryl-C<sub>1-6</sub>-alkyl, heteroaryl, heteroaryl-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkyl or C<sub>3-8</sub>-cycloalkyl wherein the ring moieties optionally may be substituted with one or more substituents independently selected from R<sup>15</sup>

  R<sup>15</sup> is
  - halogen, nitro, cyano, hydroxy, C<sub>1-6</sub>-alkylthio, C<sub>1-6</sub>-alkylsulfonyl, C<sub>1-6</sub>-alkylsulfonyloxy, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy, C<sub>3-8</sub>-cycloalkyl, halo-C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkoxy, -NR<sup>7</sup>R<sup>8</sup>, R<sup>7</sup>R<sup>8</sup>N-C<sub>1-6</sub>-alkyl-, R<sup>7</sup>R<sup>8</sup>N-C<sub>1-6</sub>-alkoxy-, or -O(C=O)NR<sup>7</sup>R<sup>8</sup>, or wherein two substituents in adjacent positions together form a radical -O-(CH<sub>2</sub>)<sub>1-3</sub>-O-, wherein R<sup>7</sup> and R<sup>8</sup> independently are hydrogen, C<sub>1-6</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl. C<sub>1-6</sub>-alkanoyl or aryl, or R<sup>7</sup> and R<sup>8</sup> together with the nitrogen atom to which they are attached form a 3 to 7 membered, saturated or unsaturated ring, which may be fused to a benzene ring,
- o NR<sup>9</sup>R<sup>10</sup> wherein R<sup>9</sup> and R<sup>10</sup> independently are hydrogen, C<sub>1-6</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl, C<sub>1-6</sub>-alkanoyl or aryl, or R<sup>9</sup> and R<sup>10</sup> together with the nitrogen atom to which they are attached form a 3 to 7 membered, saturated or unsaturated ring, which may be fused to a benzene ring, and the ring may contain further heteroatoms and it may optionally be substituted with one or more substituents independently selected from R<sup>16</sup>, wherein R<sup>16</sup> is C<sub>1-6</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl, C<sub>1-6</sub>-alkanoyl or aryl optionally substituted with one or more substituents independently selected from R<sup>17</sup>, wherein R<sup>17</sup> is halogen, nitro, cyano, hydroxy, or C<sub>1-6</sub>-alkyl;

as well as any diastereomer or enantiomer or tautomeric form, mixtures of these, or a pharmaceutically acceptable salt thereof.

- 2. (Previously presented) A compound according to claim 1, wherein R1 is C3-8-cycloalkyl.
- 3. (Currently amended) A compound according to claim 2 Error! Reference source not found: wherein R<sup>1</sup> is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

- 4. (Currently Amended) A compound according to claim 3 Error! Reference source not found, wherein R<sup>1</sup> is cyclopropyl or cyclopentyl.
- 5. Cancelled
- 6. (Currently amended) A compound according to claim 4 Error! Reference source not found, wherein R<sup>1</sup> is cyclopropyl.
- (Original) A compound according to claim 1, wherein X is a bond.
  - 1 %: (Original) A compound according to claim 1, wherein s and t together are 0, 1, 2 or 3.
    - 9. Cancelled
- X0. (Original) A compound according to claim 1 wherein s is 0 or 1.
- 9 M. (Original) A compound according to claim 10 wherein s is 0.
- 10 12 (Original) A compound according to claim I wherein t is 0.
  - 13. Cancelled
  - 14. Cancelled
  - 15. Cancelled
  - 16. Cancelled
  - 17. Cancelled
- 18. (Previously presented) A compound according to claim 1, wherein Y is selected from



- (Original) A compound according to claim 1, wherein R<sup>4</sup> is aryl, aryl-C<sub>1-6</sub>-alkyl, either of which may optionally be substituted with one or more substituents independently selected from R<sup>14</sup>, or C<sub>3-8</sub>-cycloalkyl optionally substituted with one or more substituents independently selected from R<sup>13</sup>.
- 13.20. (Original) A compound according to claim 19 wherein R<sup>4</sup> is anyl optionally substituted with one or more substituents independently selected from R<sup>14</sup>.
- 21. (Original) A compound according to claim 19 wherein R<sup>4</sup> is phenyl, biphenylyl, or naphthyl optionally substituted with one or more substituents independently selected from R<sup>14</sup>.
- 22. (Original) A compound according to claim 21, wherein R<sup>4</sup> is phenyl optionally substituted with one or more substituents independently selected from R<sup>14</sup>.
- 16 23. (Original) A compound according to claim I wherein R<sup>13</sup> is C<sub>16</sub>-alkyl.
- 24. (Original) A compound according to claim 1 wherein R<sup>14</sup> is halogen, cyano, hydroxy, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkylsulfonyl, C<sub>1-6</sub>-alkylsulfonyloxy, C<sub>1-6</sub>-alkoxy, C<sub>3-8</sub>-cycloalkyl, -CF<sub>3</sub>, -OCF<sub>3</sub>, -NR<sup>5</sup>R<sup>6</sup>, R<sup>5</sup>R<sup>6</sup>N-C<sub>1-6</sub>-alkyl-, or a group of the formula -(W)<sub>k</sub>-A.
- (% 25. (Original) A compound according to claim 24 wherein R<sup>14</sup> is F, Cl, cyano, methyl, ethyl, propyl, butyl, tert-butyl, methyl-sulfonyl, methylsulfonyloxy, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. -CF<sub>3</sub>, -OCF<sub>3</sub>, -NR<sup>5</sup>R<sup>6</sup>, R<sup>5</sup>R<sup>6</sup>N-methyl-, or a group of the formula -(W)<sub>k</sub>-A.
- F, Cl, cyano, methyl, tert-butyl, methyl-sulfonyl, methoxy, cyclopentyl, cyclohexyl,

  -CF<sub>3</sub>, -OCF<sub>3</sub>, -NR<sup>5</sup>R<sup>6</sup>, R<sup>5</sup>R<sup>6</sup>N-methyl-, or
  a group of the formula -(W)<sub>k</sub>-A.

- 27. (Original) A compound according to claim 26 wherein R<sup>14</sup> Is a group of the formula -(W)<sub>k</sub>-A.
  - 28. (Original) A compound according to claim 1, wherein k is 1.
  - 22.29. (Original) A compound according to claim 1 wherein k is 0.
- 30. (Original) A compound according to claim 1 wherein W is -C<sub>1-6</sub>-alkyl-, -(O)<sub>1</sub>-C<sub>1-6</sub>-alkyl-O-. -(CH<sub>2</sub>)<sub>n</sub>-(C=O)-(CH<sub>2</sub>)<sub>m</sub>-, or -O-.
- 31. (Original) A compound according to claim 30 wherein W is -C<sub>1-6</sub>-alkyl- or -(CH<sub>2</sub>)<sub>n</sub>-(C=0)-(CH<sub>2</sub>)<sub>m</sub>-.
- 32. (Original) A compound according to claim 31 wherein W is methylene, ethylene, propylene or -(CH<sub>2</sub>)<sub>α</sub>-(C=O)-(CH<sub>2</sub>)<sub>m</sub>-.
- 26. 33. (Original) A compound according to claim 1 wherein n is 0 or 1.
- $\sqrt{\phantom{a}}$ .34. (Original) A compound according to claim 33 wherein n is 0.
- 28. (Previously presented) A compound according to claim 1 wherein m is 0 or 1.
- 36. (Original) A compound according to claim 35 wherein m is 0.
- 37. (Original) A compound according to claim 1 wherein 1 is 0.
- 38. (Original) A compound according to claim 1 wherein A is C<sub>1-5</sub>-alkyl, aryl or C<sub>1-6</sub>-cycloalkyl, wherein the ring moieties optionally may be substituted with one or more substituents independently selected from R<sup>15</sup>, or A is NR<sup>9</sup>R<sup>10</sup>.

- 3 2 39. (Original) A compound according to claim 38 wherein A is methyl, ethyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein the ring moieties optionally may be substituted with one or more substituents independently selected from R<sup>15</sup>, or A is NR<sup>9</sup>R<sup>10</sup>.
- 35 40. (Original) A compound according to claim 39 wherein A is phenyl optionally substituted with one or more substituents independently selected from R<sup>15</sup>.
- 34 AT. (Original) A compound according to claim 40 wherein A is phenyl.
- 35 A2. (Original) A compound according to claim 39 wherein A is NR9R10.
- <sup>2</sup>/<sub>6</sub> A3. (Original) A compound according to claim 1 wherein R<sup>15</sup> is halogen, nitro, cyano, hydroxy, C<sub>1-6</sub>-alkylthio, C<sub>1-6</sub>-alkylsulfonyl, C<sub>1-6</sub>-alkylsulfonyloxy, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy, C<sub>3-8</sub>-cycloalkyl, halo-C<sub>1-6</sub>-alkyl, or halo-C<sub>1-6</sub>-alkoxy.
- 44. (Original) A compound according to claim 43 wherein R<sup>15</sup> is halogen, cyano, hydroxy, CH<sub>3</sub>-S-, CH<sub>3</sub>CH<sub>2</sub>-S-, methylsulfonyl, methylsulfonyloxy, methyl, ethyl, propyl, butyl, isopropyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, -CF<sub>3</sub>, or -OCF<sub>3</sub>.
- 38 45. (Original) A compound according to claim 44 wherein R<sup>15</sup> is halogen, methyl, ethyl, methoxy, ethoxy, -CF<sub>3</sub>, or -OCF<sub>3</sub>.
- 36. (Original) A compound according to claim 1 wherein R<sup>9</sup> and R<sup>10</sup> together with the nitrogen atom to which they are attached form a 3 to 7 membered, saturated or unsaturated ring, which may be fused to a benzene ring, and the ring may contain further heteroatoms and it may optionally be substituted with one or more substituents independently selected from R<sup>16</sup>.
- (Original) A compound according to claim 46 wherein R<sup>9</sup> and R<sup>10</sup> together with the nitrogen atom to which they are attached form a structure selected from

- 48. (Original) A compound according to claim 1 wherein R<sup>16</sup> is methyl, ethyl, 1-ethyl-propyl or phenyl optionally substituted with one or more substituents independently selected from R<sup>17</sup>.
- 42-49 (Original) A compound according to claim I wherein R<sup>17</sup> is halogen.
- (Original) A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.
- dosage form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg or and especially preferred from about 0.5 mg to about 200 mg of the compound.
- 45 52. (Original) A pharmaceutical composition according to claim 50 wherein the compound exhibits histamine H3 antagonistic activity or histamine H3 inverse agonistic activity.
  - 53. Cancelled
  - 54. Cancelled
  - ·55. Cancelled
  - 56. Cancelled
  - 57. Cancelled
  - 58. Cancelled
  - 59. Cancelled
  - 60. Cancelled
  - 61. Cancelled

- 62. Cancelled
- 63. Cancelled
- 64. Cancelled
- 65. Cancelled
- 66. Cancelled
- 67. Cancelled